Response to ketamine in status asthmaticus resistant to maximal medical treatment

Anne Hemming, Iain MacKenzie, Simon Finfer

Abstract

The case is reported of a 28 year old woman with status asthmaticus unresponsive to three days of maximal medical treatment. Resolution of bronchospasm was achieved with an infusion of the intravenous anaesthetic agent ketamine.

(Thorax 1994;49:90-91)

Ketamine is a unique intravenous anaesthetic agent with sedative, analgesic, and bronchodilator properties. Its propensity to cause distressing emergence phenomena has limited its use. It has been used successfully in patients with acute asthma but these patients had not received maximal medical treatment as judged by current standards. The treatment of acute asthma is outside the terms of its UK product licence and its role in this setting remains to be defined. This report describes its successful use in a patient in whom conventional medical treatment had failed.

Case report

A 28 year old woman with a history of asthma was admitted unconscious having suffered a respiratory arrest at home. Endotracheal intubation was performed immediately, arterial blood gases following intubation were pH 6.93, PaCO2 141 kPa, PaO2 14.0 kPa, (Fio2 1). Initial treatment was with intravenous hydrocortisone 200 mg, aminophyllyne 250 mg, and ventilation by hand with 1% halothane in oxygen. In the intensive care unit treatment was continued with intravenous aminophyllyne 0.9 mg/kg/hour, hydrocortisone 200 mg every six hours, and nebulised ipratropium bromide 500 µg four hourly. Mechanical ventilation
as barotrauma contributes to a significant number of deaths. Adopting this strategy has produced good results in the management of both adults and children with asthma.6,7 Prolonged endotracheal intubation and invasive vascular monitoring increase the risk of sepsis and barotrauma. Aggressive treatment of asthma to allow early tracheal extubation and removal of intravascular lines may reduce morbidity and mortality. The British Thoracic Society has published guidelines for the management of severe asthma in adults and our patient was managed according to these guidelines but failed to improve over three days. There are few published data on which to base the management of patients who fail to respond to maximal conventional therapy. The volatile anaesthetic agents are potent bronchodilators and have been used successfully.10-12 Ether has traditionally been used, its major advantage being that it does not cause hypotension, but it is inflammable and explosive which poses a significant risk to the patient. Halothane, enflurane and isoflurane have all been used and there are no data to support the use of one agent in preference to the others. Isoflurane has a wider therapeutic index and is the agent of first choice in our unit. Our patient failed to respond to prolonged administration of isoflurane and was therefore treated with a ketamine infusion. Ketamine is licensed for use as an intravenous anaesthetic agent but not as a sedative or bronchodilator in intensive care. Previous unlicensed use of anaesthetic agents in intensive care has been associated with increased mortality.13,14 We believe that ketamine should only be used when a patient has failed a trial of maximum conventional treatment but our experience suggests that systematic evaluation of its use in resistant status asthmaticus is justified.

Discussion

Approximately 3% of patients admitted to hospital with asthma will require mechanical ventilation and most respond to treatment with conventional bronchodilators. Deaths in patients with asthma requiring mechanical ventilation may be caused by anoxic encephalopathy (usually due to a cardiac arrest occurring before mechanical ventilation is established), barotrauma, or sepsis.6,7 The risk of barotrauma may be reduced by limiting peak inspiratory pressure while adjusting ventilation to ensure adequate oxygenation, although some hypercarbia may have to be accepted. This strategy, which has been referred to as controlled hyperventilation or permissive hypercarbia, is based on the knowledge that hypercarbia is well tolerated where-

was commenced and tidal volume was adjusted to limit peak inspiratory pressure to 30 cm H2O. A chest radiograph showed a right mid zone infiltrate but no pneumothorax. She remained ventilator dependent for the next four days during which the bronchospasm persisted despite the addition of intravenous salbutamol and inhaled isoflurane. To avoid excessive peak inspiratory pressure tidal volume had to be 400 ml or less, PaCO2 varied between 6-4 and 8-6 kPa. After 72 hours treatment was with hydrocortisone 200 mg six hourly, aminophylline 0.5 mg/kg/hour, salbutamol 10 µg/minute, ipratropium bromide 500 µg four hourly, and 2% isoflurane. Sedation and intermittent neuromuscular blockade were continued as attempts to reduce the level of sedation exacerbated the patient's bronchospasm. On day 4 the isoflurane was discontinued and an intravenous infusion of ketamine commenced at a dose of 2-5 mg/kg/hour. Within six hours the patient's chest was clear to auscultation, and gas exchange and respiratory system compliance had improved (figure). Spontaneous ventilation was established and the patient was successfully extubated 26 hours after starting the ketamine infusion; the ketamine was then discontinued. The patient regained consciousness over the following 36 hours and experienced no emergence phenomena. There was no recurrence of bronchospasm and the patient was discharged to the ward.

Response to ketamine in status asthmaticus resistant to maximal medical treatment.

A Hemming, I MacKenzie and S Finfer

Thorax 1994 49: 90-91
doi: 10.1136/thx.49.1.90

Updated information and services can be found at:
http://thorax.bmj.com/content/49/1/90

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/